Find a Physician How to Contribute Affiliated Hospitals Clinical Trials

Search Clinical Trials
Protocol DRUG SGI-110-03

Title A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Purpose The purpose of the study is to evaluate the safety, tolerability and effectiveness of SGI-110, and any potential benefits, in patients with hepatocellular cancer (HCC) who progressed (gotten worse) after treatment with sorafenib.
Overview This study is for patients who have advanced liver cancer called HCC that has come back despite treatment with sorafenib. The drug being studies in this clinical trial, SGI-110, breaks down in the body into a compound called decitabine. Decitabine is an FDA-approved drug for the treatment of a disease of blood cells called myelodysplastic syndromes (MDS). Decitabine (and therefore the study drug) blocks abnormal cells or cancer cells from growing.
Who May
be Eligible
Some of the eligibility criteria include:
  • Study participants must have advanced hepatocellular cancer.
  • Participants must be 18 or older.
  • Participants tumor must have grown while taking the drug sorafenib.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.

Description of Treatment In this study, the study drug will be given as a subcutaneous injection (a shot just below the skin) on Days 1-5. Participants will then have approximately three weeks with no treatment until the treatment cycle is repeated. The treatment cycles will be 28 days long. After the end of the 28 days participants may begin the next treatment cycle (new treatment cycle on Day 29). Treatment cycles may continue as long as participants are not having unacceptable side effects and are not getting worse.

Clinical trial availability changes frequently. Please check this site for new or updated trials that pertain to you.
If you have questions about current or future trials, contact the Cancer Center at 866-LURIE-CC (866-587-4322) or
About Us | Job Opportunities | Northwestern University | Maps & Directions | Contact Us
© Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Clinical Cancer Center: 866.LURIE.CC || Chicago Administrative Office: 312.908.5250.
Contact us with questions at:
National Comprhensive Cancer Network National Cancer Institute You Tube Facebook